Screener
Summit Therapeutics SMMT Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development (1) | $132,618 | $51,265 |
| General and administrative | 62,594 | 15,586 |
| Total operating expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
| Net loss per share: | ||
| Basic and diluted | $(0.24) | $(0.09) |
| Weighted average common shares outstanding: |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's other income (expense)?
- Summit Therapeutics (SMMT) reported other income (expense) of $5.79M in Q1 2026.
- How has Summit Therapeutics's other income (expense) changed year-over-year?
- Summit Therapeutics's other income (expense) increased by 47.0% year-over-year, from $3.94M to $5.79M.
- What is the long-term trend for Summit Therapeutics's other income (expense)?
- Over 3 years (2021 to 2025), Summit Therapeutics's other income (expense) has grown at a 83.1% compound annual growth rate (CAGR), from -$2.42M to $14.84M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Summit Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude